Diabetes research and clinical practice · 2020
Review of methods for detecting glycemic disorders.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bergman Michael, Abdul-Ghani Muhammad, DeFronzo Ralph A, Manco Melania, Sesti Giorgio, Fiorentino Teresa Vanessa, Ceriello Antonio, Rhee Mary, Phillips Lawrence S, Chung Stephanie, Cravalho Celeste, Jagannathan Ram, Monnier Louis, Colette Claude, Owens David, Bianchi Cristina, Del Prato Stefano, Monteiro Mariana P, Neves João Sérgio, Medina Jose Luiz, Macedo Maria Paula, Ribeiro Rogério Tavares, Filipe Raposo João, Dorcely Brenda, Ibrahim Nouran, Buysschaert Martin
Аннотация
Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overBiomarkersBlood GlucoseBlood Glucose Self-MonitoringCardiovascular DiseasesChildDiabetes Mellitus, Type 2FemaleFructosamineGlucose IntoleranceGlucose Metabolism DisordersGlucose Tolerance TestGlycated HemoglobinGlycation End Products, AdvancedHumansHyperglycemiaLongitudinal StudiesMaleMiddle AgedPrediabetic StateSerum AlbuminYoung AdultGlycated Serum Albumin